Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | IL5 | P05113 | 1/20 | 0.35 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17532790 | 0.87 | CYP1A2 (0.44) | CYP1A2CYP2A6KDM4EMAPTLMNA | |
| SCHEMBL17532780 | 0.79 | KDM4E (0.40) | CYP1A2KDM4EMAPTLMNAHTT | |
| SCHEMBL17532793 | 0.77 | KDM4E (0.42) | CYP1A2CYP2A6KDM4EMAPTLMNA | |
| SCHEMBL17532785 | 0.76 | CYP1A2 (0.54) | CYP1A2CYP2A6KDM4EMAPTLMNA | |
| SCHEMBL17532779 | 0.74 | CYP1A2 (0.42) | CYP1A2CYP2A6KDM4EMAPTLMNA | |
| SCHEMBL17532735 | 0.73 | KDM4E (0.50) | CYP1A2CYP2A6KDM4EMAPTLMNA | |
| SCHEMBL17532783 | 0.73 | TOP2A (0.38) | CYP2A6KDM4EMAPTLMNAHTT | |
| SCHEMBL17532775 | 0.73 | CYP2A6 (0.40) | CYP1A2CYP2A6KDM4EMAPTLMNA | |
| SCHEMBL17532760 | 0.71 | PDPK1 (0.49) | CYP1A2CYP2A6KDM4EMAPTLMNA | |
| SCHEMBL18266952 | 0.71 | CYP2A6 (0.50) | CYP1A2CYP2A6CCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9780310-B2 | Heterocyclic compound for organic electroluminescent device and its application | TOSOH CORPORATION (JP) | 2017-10-03 | — | — | US | disclosed |
| US-20160056388-A1 | HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION | TOSOH CORPORATION (JP) | 2016-02-25 | — | — | US | disclosed |
| US-20160056388-A1 | HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION | TOSOH CORPORATION (JP) | 2016-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160056388-A1 | HETEROCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENT DEVICE AND ITS APPLICATION | AOC2, AZI2, KCNH2 | CYP1A2 978/4885CYP2A6 3145/4885KDM4E 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.